2 results match your criteria: "CHRISTUS Research Institute[Affiliation]"
Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies.
Curr Opin Urol
January 2018
CHRISTUS Santa Rosa Medical Center Hospital, CHRISTUS Research Institute, San Antonio, Texas, USA.
Purpose Of Review: We review the concepts surrounding prostate cancer prevention strategies with 5-alpha reductase inhibitors (5-ARIs) and the controversies associated with their use.
Recent Findings: Updated data have shown no increased risk of death from the diagnosis of higher risk cancer; however, 5-ARIs remain controversial and not approved for prostate cancer prevention.
Summary: The main theme of the review identifies the success of reducing insignificant prostate cancer and the controversy with the increased association of higher risk prostate cancer by approximately 20%.
Introduction to Ochsner's Thirteenth Annual Research Day.
Ochsner J
September 2016
System Vice President for Research, Ochsner Health System; Professor and Deputy Head for Research, The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA; Dr Rao is currently System Vice President and Chief Academic Officer, CHRISTUS Health, Irving, TX, and Executive Director, CHRISTUS Research Institute.